Advertisement
Advertisement
As of 01:34PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 45.82 |
| Open | 45.75 |
| Bid | 45.33 x 1000 |
| Ask | 45.37 x 800 |
| Day's Range | 45.07 - 46.16 |
| 52 Week Range | 34.00 - 63.00 |
| Volume | |
| Avg. Volume | 1,069,823 |
| Market Cap | 5.429B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.49 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.14 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Natera, Inc.Analyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services is designed to accelerate and simplify genetic analysis. Illumina also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 10,200 full-time employees. ILMN shares are included in the S&P 500 index.RatingFair ValueEconomic Moat3 days agoArgus Research
Business WireNatera Announces Senior Leadership Appointments
AUSTIN, Texas, September 18, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
GuruFocus.comUnveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive Guide
An in-depth look at Natera Inc's valuation and financial performance
Business WireNatera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
AUSTIN, Texas, September 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
